GlassScriptPhysician profile
Bruce R Mayerson
NPI 1477657666
$8,272.06
in general payments reported to CMS, 2019-2025
45 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $311 · 2021: $554 · 2022: $929 · 2023: $1,322 · 2024: $2,130 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,219 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,219.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,673.26 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $437.34 | 2022-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $420.59 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Lundbeck LLC | $418.72 | 2020-2025 | Vyepti, Rexulti |
| Ucb, INC. | $404.59 | 2022-2025 | Rystiggo, Fintepla, Zilbrysq |
| Celgene Corporation | $389.13 | 2021-2025 | Zeposia |
| Sk Life Science, INC. | $381.01 | 2020-2025 | |
| Biogen, INC. | $377.32 | 2021-2025 | Vumerity |
| Eisai INC. | $352.61 | 2021-2025 | |
| Pfizer INC. | $333.12 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $317.46 | 2022-2025 | Nuplazid |
| Acorda Therapeutics, INC | $311.97 | 2019-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $211.09 | 2020-2022 | |
| Grifols USA, LLC | $177.75 | 2023-2025 | Gamunex-C, Xembify |
| Amneal Pharmaceuticals LLC | $163.29 | 2022-2025 | Crexont, Ongentys 50mg Capsules 30 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Mayerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.